Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) Shares Outstanding (Weighted Average) (2022 - 2025)

Historic Shares Outstanding (Weighted Average) for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to $134.2 million.

  • Centessa Pharmaceuticals' Shares Outstanding (Weighted Average) rose 1540.56% to $134.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $134.2 million, marking a year-over-year increase of 1540.56%. This contributed to the annual value of $114.5 million for FY2024, which is 1902.3% up from last year.
  • Latest data reveals that Centessa Pharmaceuticals reported Shares Outstanding (Weighted Average) of $134.2 million as of Q3 2025, which was up 1540.56% from $133.7 million recorded in Q2 2025.
  • In the past 5 years, Centessa Pharmaceuticals' Shares Outstanding (Weighted Average) registered a high of $134.2 million during Q3 2025, and its lowest value of $90.5 million during Q1 2022.
  • Moreover, its 4-year median value for Shares Outstanding (Weighted Average) was $96.6 million (2023), whereas its average is $106.4 million.
  • In the last 5 years, Centessa Pharmaceuticals' Shares Outstanding (Weighted Average) soared by 111.96% in 2023 and then skyrocketed by 3318.31% in 2025.
  • Quarter analysis of 4 years shows Centessa Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $93.4 million in 2022, then increased by 2.97% to $96.2 million in 2023, then grew by 19.02% to $114.5 million in 2024, then rose by 17.2% to $134.2 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $134.2 million for Q3 2025, versus $133.7 million for Q2 2025 and $133.0 million for Q1 2025.